Adjusted EBITDA* was $8.0 million (8.8% of revenue) in FY25, compared to $12.0 million in FY24 (17.5% of revenue). CTW maintained positive Adjusted EBITDA while actively supporting new game launches ...

The financial arrangement for the global Phase III program in common warts, where by Verrica and Torii split the cost of the program with the first $40 million funded by Torii has unlocked the ...

Q3 2025 Earnings Call November 17, 2025 7:30 AM ESTCompany ParticipantsPu Huang - Investor Relations Officer - ChinaCharles Zhang ...

Guidance for both non-GAAP and GAAP net loss attributable to Sohu.com Limited ( SOHU 3.18%) for 2025 is projected to be ...

Google Home v4.3 launches with Gemini AI, a full Nest integration, and a redesign that makes the app 70% faster. See the new ...

Executive Transition -- CFO Barry Neil Berlin will exit following the lending business sale, with Brandon Hill assuming the ...

Spectrum segment revenue and adjusted EBITDA declined by $800,000 and $700,000, respectively, due to "the termination of ...

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved ...

Katapult Holdings, Inc. (NASDAQ: KPLT) Q3 2025 Earnings Call Transcript November 12, 2025 Katapult Holdings, Inc. beats ...

Wearables, Mobile Health (m-Health), Real-Time Monitoring Share and Cite: Alqarni, A. (2025) Analysis of Decision Support ...

Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...

Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination withatirmociclib in ER+/HER2- metastatic breast ...